AU2009243813B2 - Method for treating cognitive deficits - Google Patents

Method for treating cognitive deficits Download PDF

Info

Publication number
AU2009243813B2
AU2009243813B2 AU2009243813A AU2009243813A AU2009243813B2 AU 2009243813 B2 AU2009243813 B2 AU 2009243813B2 AU 2009243813 A AU2009243813 A AU 2009243813A AU 2009243813 A AU2009243813 A AU 2009243813A AU 2009243813 B2 AU2009243813 B2 AU 2009243813B2
Authority
AU
Australia
Prior art keywords
compound
cognitive
salt
phenylindan
trimethylpiperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009243813A
Other languages
English (en)
Other versions
AU2009243813A1 (en
Inventor
Lone Bruun
Klaus Peter Hertel
Rene Holm
Christine Kau
Christina Kurre Olsen
Karina Krojer Soby
Birgitte Willumsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU2009243813A1 publication Critical patent/AU2009243813A1/en
Application granted granted Critical
Publication of AU2009243813B2 publication Critical patent/AU2009243813B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2009243813A 2008-05-07 2009-05-07 Method for treating cognitive deficits Ceased AU2009243813B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200800647 2008-05-07
DKPA200800647 2008-05-07
DKPA200801392 2008-10-03
DKPA200801392 2008-10-03
DKPA200801519 2008-11-04
DKPA200801519 2008-11-04
PCT/DK2009/050107 WO2009135495A1 (en) 2008-05-07 2009-05-07 Method for treating cognitive deficits

Publications (2)

Publication Number Publication Date
AU2009243813A1 AU2009243813A1 (en) 2009-11-12
AU2009243813B2 true AU2009243813B2 (en) 2014-05-29

Family

ID=40870955

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009243813A Ceased AU2009243813B2 (en) 2008-05-07 2009-05-07 Method for treating cognitive deficits

Country Status (15)

Country Link
US (2) US20090306092A1 (enExample)
EP (1) EP2285377A1 (enExample)
JP (1) JP2011519873A (enExample)
KR (1) KR20110021754A (enExample)
CN (1) CN102065861B (enExample)
AU (1) AU2009243813B2 (enExample)
BR (1) BRPI0912223A2 (enExample)
CA (1) CA2722374A1 (enExample)
CO (1) CO6311083A2 (enExample)
EA (1) EA018927B1 (enExample)
IL (1) IL209084A0 (enExample)
MX (1) MX2010012037A (enExample)
NZ (1) NZ589571A (enExample)
WO (1) WO2009135495A1 (enExample)
ZA (1) ZA201007912B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012504560A (ja) * 2008-10-03 2012-02-23 ハー・ルンドベック・アクチエゼルスカベット 経口製剤
LT3135656T (lt) 2011-06-20 2019-04-25 H. Lundbeck A/S Deuterinti 1-piperazin-3-fenilindanai, skirti šizofrenijos gydymui
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
CN112930341A (zh) * 2018-10-29 2021-06-08 H.隆德贝克有限公司 无定形的具有式(i)的化合物和无定形的具有式(i)的化合物的盐
CN113056457B (zh) 2018-12-03 2025-06-20 H.隆德贝克有限公司 用于治疗cns疾病的前药

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022293A1 (en) * 1992-04-28 1993-11-11 H. Lundbeck A/S 1-piperazino-1,2-dihydroindene derivatives
WO2005016900A1 (en) * 2003-08-18 2005-02-24 H. Lundbeck A/S Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
WO2006086985A1 (en) * 2005-02-16 2006-08-24 H. Lundbeck A/S Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
WO2006086986A1 (en) * 2005-02-16 2006-08-24 H. Lundbeck A/S Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031216A (en) * 1974-08-12 1977-06-21 Knoll A.G. Chemische Fabriken 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
IE50867B1 (en) * 1980-02-29 1986-08-06 Kefalas As Indane derivatives
DE3139970A1 (de) * 1981-10-08 1983-04-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en) * 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
CA2091204C (en) * 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
CA2132411A1 (en) * 1994-09-19 1996-03-20 Michael Trani Enzymatic esterification of long-chain racemic acids and alcohols
US6410794B1 (en) * 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US6455736B1 (en) * 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US5807897A (en) * 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
ES2211080T3 (es) * 1998-05-01 2004-07-01 Pfizer Products Inc. Procedimiento para la produccion de sertralina tetralona enantiomericamente pura u opticamente enriquecida usando cromatografia continua.
DE19824470A1 (de) * 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
IN187170B (enExample) * 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
AU2002359857B8 (en) * 2001-12-28 2009-01-08 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
WO2004039322A2 (en) * 2002-10-29 2004-05-13 Miicro, Inc. Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
TW200640891A (en) * 2005-02-16 2006-12-01 Lundbeck & Co As H Tartrate and malate salts of a pharmarceutical compound
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
JP2012504560A (ja) * 2008-10-03 2012-02-23 ハー・ルンドベック・アクチエゼルスカベット 経口製剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022293A1 (en) * 1992-04-28 1993-11-11 H. Lundbeck A/S 1-piperazino-1,2-dihydroindene derivatives
WO2005016900A1 (en) * 2003-08-18 2005-02-24 H. Lundbeck A/S Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
WO2006086985A1 (en) * 2005-02-16 2006-08-24 H. Lundbeck A/S Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
WO2006086986A1 (en) * 2005-02-16 2006-08-24 H. Lundbeck A/S Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOGESO, K.P. et al. "Enhanced D1 Affinity in a Series of Piperazine Ring Substituted 1-Piperazino- 3-Arylindans with Potential Atypical Antipsychotic Activity" Journal of Medicinal Chemistry (1995) Vol.38 No.22 pages 4380 to 4392 *

Also Published As

Publication number Publication date
NZ589571A (en) 2012-07-27
CN102065861A (zh) 2011-05-18
CN102065861B (zh) 2013-10-16
IL209084A0 (en) 2011-01-31
KR20110021754A (ko) 2011-03-04
WO2009135495A1 (en) 2009-11-12
CA2722374A1 (en) 2009-11-12
HK1157674A1 (en) 2012-07-06
ZA201007912B (en) 2012-02-29
JP2011519873A (ja) 2011-07-14
EA018927B1 (ru) 2013-11-29
US20090306092A1 (en) 2009-12-10
US20110207744A1 (en) 2011-08-25
EP2285377A1 (en) 2011-02-23
BRPI0912223A2 (pt) 2015-10-06
AU2009243813A1 (en) 2009-11-12
MX2010012037A (es) 2010-11-30
EA201071273A1 (ru) 2011-06-30
CO6311083A2 (es) 2011-08-22

Similar Documents

Publication Publication Date Title
US20110207744A1 (en) Method for treating cognitive deficits
JP2012504560A (ja) 経口製剤
Meneses et al. 5-HT1AReceptors Modulate the Consolidation of Learning in Normal and Cognitively Impaired Rats
RS49828B (sr) Farmaceutski sastavi
CN107810002A (zh) 左乙拉西坦的延时释放药物组合物
CA2478227A1 (en) Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
WO2021016369A1 (en) Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
BRPI0715445A2 (pt) Uso de um composto de bifeprunox, e, kit de titulação
JP2020075933A (ja) ストレス性疾患の予防および／または治療用医薬
EP3952872B1 (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
JP2008156297A (ja) セロトニン２ｂおよび／または２ｃ受容体拮抗剤
JP2004502655A (ja) 精神病の処置のための組み合わせ療法
Ishida et al. Effects of some antipsychotics and a benzodiazepine hypnotic on the sleep-wake pattern in an animal model of schizophrenia
Maguire Impact of antipsychotics on geriatric patients: efficacy, dosing, and compliance
Freudenreich et al. 7 Antipsychotic Drugs
HK1157674B (en) Use of trans-4((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine for improving cognition
CN114761008B (zh) 用于在患有痴呆的患者中治疗行为和心理症状的方法
CA3162938C (en) Methods for treating behavioral and psychological symptoms in patients with dementia
WO2023036820A1 (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
HK40071167A (en) Methods for treating behavioral and psychological symptoms in patients with dementia
HK40067131A (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HK40067131B (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
Ayd Jr Tardive dyskinesia: Recent developments
Rappard et al. P. 3. c. 056 Efficacy of ziprasidone in the treatment of schizoaffective disorder: an analysis of 2 fixed-dose, placebo-controlled trials
HK1161118A (en) Oral formulation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired